"Fujifilm Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, announced a 10-year manufacturing supply agreement, valued at over $3 billion, with Regeneron Pharmaceuticals, Inc. to provide US-based production of its industry-leading biologic medicines, which treat millions of patients worldwide.
Under the terms of the agreement, Fujifilm Diosynth Biotechnologies will provide US-based manufacturing for Regeneron over the 10-year period through current and planned expansions at its new large-scale biopharmaceutical manufacturing facility in Holly Springs, North Carolina, when the site begins operations later this year (2025).
“This agreement with an industry-leading biologic medicines company demonstrates that Fujifilm Diosynth Biotechnologies is trusted by our partners to deliver through our technical expertise, talented team, and operational readiness,” said Toshihisa Iida, director, corporate vice president, general manager of Life Sciences Strategy Headquarters and Bio-CDMO Division, Fujifilm Corporation, Japan. “Fujifilm Diosynth Biotechnologies will be bringing additional capacity online in 2025, 2026 and beyond as it completes the current $7 billion of expansion projects underway in both Europe and United States.”?
“We are delighted to be selected as the manufacturing supply partner for Regeneron, utilizing our new state-of-the-art facility in Holly Springs, North Carolina. The Holly Springs site is part of our kojoX interconnected manufacturing network, which provides a first-of-its-kind modular approach with standardized equipment, processes, and procedures across our sites around the globe to help ensure supply chain security and seamless tech transfers,” said Lars Petersen, president and chief executive officer, Fujifilm Diosynth Biotechnologies. “Partnering with Regeneron, a global leader in biotechnology and scientific innovation, is a true honour for us, as we bring together our exceptional teams and shared vision to make transformative medicine accessible to patients. We are honoured that Regeneron has the trust and confidence in our team’s ability to help deliver capacity faster, ensuring continuity of supply for patients in need.”
“At Regeneron, we have the privilege of making some of the best and most innovative therapeutics in the industry, and we are acutely aware of Regeneron’s impact on people’s lives as we work to help treat or even cure devastating diseases,” said Daniel Van Plew, executive vice president and general manager, Industrial Operations and Product Supply at Regeneron. “We take our role seriously, and our decision to work with Fujifilm Diosynth Biotechnologies reflects our belief that they will meet our high standards and grow with us. We are excited about this unique relationship, and we are already working to bring capacity online at Fujifilm Diosynth Biotechnologies’ biologics manufacturing facility in Holly Springs, North Carolina.”
“As the US is the largest market for biopharmaceuticals, Fujifilm Corporation has made significant investments in the US of about $4 billion in building world-class biopharmaceutical manufacturing sites, life sciences capabilities, and growing its technical talent,” added Iida. “Additionally, through our previously announced expansion efforts, we are pleased to share that we’ve already added 500 new positions as part of our overall goal of creating 1,400 new jobs in North Carolina by 2031.”
Fujifilm Diosynth Biotechnologies, a subsidiary of Fujifilm Corporation, is a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines and advanced therapies. With over 30 years of experience, the company specializes in developing and manufacturing biopharmaceuticals using microbial, mammalian, and host/virus systems."